Inovio Pharmaceuticals (INO) Receivables (2010 - 2026)
Inovio Pharmaceuticals (INO) posted Receivables of $34000.0 for Q1 2026, down 10.53% sequentially from $38000.0 in Q4 2025, and down 97.41% YoY from $1.3 million in Q1 2025.
Inovio Pharmaceuticals (INO) Receivables (2010 - 2026) Analysis & Trends
Inovio Pharmaceuticals has reported Receivables for 17 years, with the latest figure at $34000.0 in Q1 2026.
- Quarterly Receivables fell 97.41% year-over-year to $34000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $34000.0 (down 97.41% YoY) and the FY2025 annual result came in at $38000.0, down 96.83% from the prior year.
- Receivables fell to $34000.0 in Q1 2026 per INO's latest filing, from $38000.0 in the prior quarter.
- Over five years, Receivables peaked at $11.4 million in Q2 2022 and troughed at $34000.0 in Q1 2026.
- A 5-year average of $3.4 million and a median of $1.8 million in 2024 frame the typical range for Receivables.
- The sharpest annual moves came in 2022 and 2026: Receivables surged 41.48% in 2022, then plunged 97.41% in 2026.
- Over 5 years, Receivables stood at $1.8 million in 2022, then jumped by 36.74% to $2.4 million in 2023, then tumbled by 50.15% to $1.2 million in 2024, then plunged by 96.83% to $38000.0 in 2025, then slipped by 10.53% to $34000.0 in 2026.
- According to Business Quant data, Receivables over the past three periods registered $34000.0, $38000.0, and $978590.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.05 Bn | 131.20 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 78.00 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 65.49 Bn | 60.31 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 56.79 Bn | 51.65 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 42.14 Bn | 37.05 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.27 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 27.71 Bn | 9.32 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.51 Bn | - | - |
| 10 | Inovio Pharmaceuticals | 95.49 Mn | 95.49 Mn | - | 41,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 41,000.00 |
| Mar 31, 2026 | 34,000.00 |
| Dec 31, 2025 | 38,000.00 |
| Sep 30, 2025 | 978,590.00 |
| Jun 30, 2025 | 840,312.00 |
| Mar 31, 2025 | 1.31 Mn |
| Dec 31, 2024 | 1.20 Mn |
| Sep 30, 2024 | 1.86 Mn |
| Jun 30, 2024 | 1.77 Mn |
| Mar 31, 2024 | 2.55 Mn |
| Dec 31, 2023 | 2.41 Mn |
| Jun 30, 2023 | 5.11 Mn |
| Mar 31, 2023 | 5.04 Mn |
| Dec 31, 2022 | 1.76 Mn |
| Sep 30, 2022 | 10.08 Mn |
| Jun 30, 2022 | 11.37 Mn |
| Mar 31, 2022 | 7.49 Mn |
| Dec 31, 2021 | 1.93 Mn |
| Sep 30, 2021 | 7.13 Mn |
| Jun 30, 2021 | 26.03 Mn |